LIMP-2 Peptides for Glucocerebrosidase Delivery and Viral Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease and Gaucher's disease lack effective methods to increase glucocerebrosidase activity, which is crucial for managing these conditions, as existing therapies face challenges in efficiently activating and delivering the enzyme to lysosomes.
Innovation Solution
Development of LIMP-2 peptides and polypeptides that bind and activate glucocerebrosidase, facilitating its transport to lysosomes and enhancing its activity, while also binding to viral proteins to prevent infections, using specific amino acid sequences and modifications to ensure biological activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat Parkinson's disease and Gaucher's disease, then treatment is provided, but glucocerebrosidase activity cannot be effectively increased
Solution Approach 1:
The patent uses LIMP-2 peptides as intermediary molecules that bind to glucocerebrosidase and facilitate its transport to lysosomes. The peptide acts as a mediator between the enzyme and the lysosomal system, enabling effective delivery and activation without requiring complex manufacturing processes for whole enzyme replacement
Solution Approach 2:
The invention extracts the critical functional domain from the full LIMP-2 protein, using only the essential peptide sequence (amino acids 152-175) that contains the glucocerebrosidase-binding capability. This extracted peptide is sufficient to activate the enzyme and deliver it to lysosomes, simplifying the therapeutic agent while maintaining efficacy
2Reliability
If LIMP-2 peptides are designed to bind glucocerebrosidase, then enzyme activation is achieved, but peptide stability and biological activity must be maintained
Solution Approach 1:
The patent employs amino acid modifications and substitutions in the LIMP-2 peptide sequence to optimize both stability and biological activity. By changing specific parameters of the peptide composition (such as adding disulfide bridges, modifying amino acid side chains, or adjusting the peptide backbone), the invention enhances peptide stability while preserving its ability to bind and activate glucocerebrosidase
Solution Approach 2:
The invention creates composite peptide structures by combining the LIMP-2 binding sequence with stabilizing elements such as cell-penetrating peptides or protective modifications. This composite approach allows the peptide to maintain both its enzyme-binding function and enhanced stability in biological environments
3Reliability
If LIMP-2 peptides are used to activate glucocerebrosidase, then treatment for Parkinson's and Gaucher's disease is improved, but the ability to prevent viral infections is lost
Solution Approach 1:
The patent identifies that LIMP-2 peptides can serve multiple functions: they activate glucocerebrosidase for treating Parkinson's and Gaucher's diseases, and simultaneously bind to viral proteins (such as enterovirus VP1) to prevent infections. This multi-functional peptide addresses multiple medical needs with a single therapeutic agent
Solution Approach 2:
The invention segments the LIMP-2 protein into distinct functional domains, with specific regions capable of binding glucocerebrosidase and other regions capable of binding viral proteins. By utilizing different segments or combinations of segments, the peptide can selectively perform either enzyme activation or antiviral functions, or both simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LIMP-2 peptides and polypeptides effectively increase glucocerebrosidase activity, providing a potential treatment for Parkinson's disease and Gaucher's disease by enhancing enzyme delivery to lysosomes and demonstrating binding capabilities to viral proteins, thus offering a dual therapeutic and preventive approach.
Implementation Method 1
a small peptide sufficient to bind and activate GCase
Implementation Method 2
binding viral proteins such as viral proteins of enterovirus 71 (E71) and coxsackievirus A16 (CA16)
Data Source
AI summary
A group of LIMP-2 peptides, LIMP-2 polypeptides, variants thereof, and pharmaceutical compositions comprising the LIMP-2 peptides, LIMP-2 polypeptides, or variants thereof are described. The disclosed peptides and polypeptides preferably comprise an amino acid sequence that is sufficient for providing a biological activity associated with LIMP-2, which may include binding and/or activating biological molecules such as β-glucocerebrosidase and binding viral protein 1 (VP1) of enterovirus 71 (E71) or coxsackievirus A16 (CA16). Also disclosed are methods of using the LIMP-2 peptides, LIMP-2 polypeptides, and variants thereof as therapeutics for treating diseases and disorders associated with β-glucocerebrosidase activity in subjects in need thereof.